Abbvie's Crohn's Disease Drug Skyrizi Shows More Positive Results
By Katherine Hamilton
Abbvie's latest findings from a trial of its drug Skyrizi found that 36% patients with Crohn's disease achieved what it described as endoscopic remission, or a healing of the intestinal lining with little to no visible inflammation.
The drug company said Tuesday that the Phase 3 Affirm study built on previously reported efficacy results. Across subgroups 36% of patients who had ulcers at the start of the study were ulcer-free by the its conclusion. Among advanced therapy-naive patients, rates were higher with 45% achieving endoscopic remission and 49% achieving ulcer-free endoscopy.
Crohn's is a chronic, systemic disease that causes inflammation within the gastrointestinal tract, most commonly in the area between the small intestine and the colon, Abbvie said.
Subcutaneous induction with Skyrizi for adults with Crohn's is currently under regulatory review with the Food and Drug Administration and the European Medicines Agency.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
October 13, 2026 16:01 ET (20:01 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States